Claims for Patent: 9,907,859

Summary for Patent: 9,907,859

Title:	ST-246 liquid formulations and methods
Abstract:	The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.
Inventor(s):	Tyavanagimatt; Shanthakumar R. (Corvallis, OR), Anderson; Melialani A. C. L. S. (Corvallis, OR), Weimers; William (Corvallis, OR), Kasi; Gopi Krishna (Lynnwood, WA), Samuel; N K Peter (Corvallis, OR), Bolken; Tove' C. (Keizer, OR), Hruby; Dennis E. (Albany, OR)
Assignee:	Siga Technologies, Inc. (Corvallis, OR)
Application Number:	14/955,674
Patent Claims:	1. A method of treating orthopoxvirus infections and/or eczema vaccinatum comprising administering to a subject in need thereof a liquid pharmaceutical formulation comprising a therapeutically effective amount of ST-246 and hydroxypropyl-.beta.-cyclodextrin and/or sulfobutyl-ether-.beta.-cyclodextrin, and further comprising one or more pharmaceutically acceptable ingredients. 2. The method of claim 1, wherein said liquid formulation is administered by parenteral administration. 3. The method of claim 1, wherein said liquid formulation is administered by oral administration. 4. The method of claim 1, wherein said liquid formulation is administered by topical administration. 5. The method of claim 1, wherein said liquid formulation is administered by intravenous administration. 6. The method of claim 5, wherein about 50 to about 500 mg of ST-246 is infused per single session of intravenous administration. 7. The method of claim 5, wherein about 200 to about 400 mg of ST-246 is infused per single session of intravenous administration. 8. The method of claim 5, wherein about 300 mg of ST-246 is infused per single session of intravenous administration. 9. The method of claim 5, wherein said treatment is carried out for a period ranging from about 7 to about 30 days. 10. The method of claim 5, wherein said treatment is carried out for a period ranging from about 7 to about 15 days. 11. The method of claim 5, wherein the duration of each session of intravenous administration is from about 2 to about 24 hours. 12. The method of claim 5, wherein said treatment is carried out continuously over the course of treatment at a dosage of about 50 to about 500 mg of ST-246 per day. 13. The method of claim 5, wherein said intravenous administration is carried out during two sessions per day. 14. The method of claim 13, wherein the duration of each session is from about 2 to about 12 hours.